Day: October 18, 2021

´╗┐However, reasons for non-persistence could also highlight problems with tolerability and effectiveness of a drug. thromboembolism 14.1%; hypertension 84.3%) and high bleeding risk (HAS-BLED score3 68.4%) was common. Apixaban-prescribed patients had more frequent history of stroke/TIA (19.7%) and high bleeding risk (72.6%) than other OACs. 12-month persistence rates were: VKA 57.5% (95% confidence interval (CI) […]